Press Release: Bioserve India Launches Advanced Stem Cell Products
22 July 2024
Hyderabad, India – July 2024 – Bioserve India is excited to announce the launch of its advanced stem cell products in India. These new products from REPROCELL aims to support innovation in scientific research and drug development, supportin...
REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
30 May 2024
REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for generation of Human Induced Pluripotent Cells (hiPSC) and Human Mesenchymal Stem Cells (hMSC) for human therapeutic applications. BELTSVILLE, ...
PRESS RELEASE: Our StemRNA Clinical Seed iPSCs Power Breakthrough in Women's Health!
16 May 2024
REPROCELL is thrilled to share groundbreaking research facilitated by our StemRNA™ Clinical Seed iPSCs, a pivotal step forward in redefining women's healthcare. In tandem with our partner Gameto, a female-led biotechnology company, we provi...
New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion
18 April 2024
REPROCELL is pleased to announce the offering of Master Cell Bank (MCB) manufacturing service for the generation of Human Induced Pluripotent Cells (hiPSC) in Beltsville for human therapeutic applications. REPROCELL has been producing clini...
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
31 January 2024
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant, that is located in Larrabetzu, Spain. Histocell's manufacturing plant produces cell ther...
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
15 January 2024
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cel...
End of 2023 Newsletter
15 December 2023
The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This inclu...
Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services
11 July 2023
COLCHESTER, VERMONT and YOKOHAMA, Japan, 11 July 2023 – Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in J...
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
25 May 2023
Yokohama Japan, 25 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic adipose-derived mesenchymal stem cells) for th...
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
23 May 2023
Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell. REPROCELL’s subcontracting pa...